Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity

Multiple Sclerosis

Volumn 13, Issue 2, 2007, Pages 208-214

  Sominanda, A ^a   Rot, U ^b   Suoniemi, M ^a   Deisenhammer, F ^c   Hillert, J ^a   Fogdell Hahn, Anna ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Immunogenicity; Interferon beta; Multiple sclerosis; Neutralizing antibodies; Seroprevalance

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

ANTIBODY TITER; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; SEROPREVALENCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBODIES; BIOLOGICAL RESPONSE MODIFIERS; CELL LINE, TUMOR; FEMALE; HUMANS; INTERFERON-BETA; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUTRALIZATION TESTS; SEROEPIDEMIOLOGIC STUDIES;

EID: 34247092348     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458506070762     Document Type: Article

References (21)

1. Schellekens H, Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 2004; 251: II4-9.
2. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-94.
3. PRISMS-4. Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56: 1628-36.
4. Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005; 65: 40-47.
5. Francis GS, Rice GP, Alsop JC. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65: 48-55.
6. Bertolotto A, Deisenhammer F, Gallo P, Solberg Sorensen P. Immunogenicity of interferon beta: differences among products. J Neurol 2004; 251: II15-24.
7. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002; 1: 457-62.
8. Ross C, Clemmesen KM, Svenson M, Sorensen PS, Koch-Henriksen N, Skovgaard GL et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000; 48: 706-12.
9. Perini P, Facchinetti A, Bulian P, Massaro AR, Pascalis DD, Bertolotto A et al. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw 2001; 12: 56-61.
10. Schellekens H. The immunogenicity of biopharmaceuticals. Neurology 2003; 61: S11-12.
11. Pungor E Jr, Files JG, Gabe JD, Do LT, Foley WP, Gray JL et al. A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. J Interferon Cytokine Res 1998; 18: 1025-30.
12. Hartung HP, Munschauer F 3rd, Schellekens H. Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference. Eur J Neurol 2005; 12: 588-601.
13. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ et al. Intramuscular interferon beta-1a therapy initiated during a first demye-linating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898-904.
14. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-82.
15. Kawade Y. Quantitation of neutralization of interferon by antibody. Methods Enzymol 1986; 119: 558-73.
16. Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M et al. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002; 59: 1507-17.
17. Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998; 50: 1266-72.
18. Herndon RM, Rudick RA, Munschauer FE 3rd, Mass MK, Salazar AM, Coats ME et al. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. Mult Scler 2005; 11: 409-19.
19. Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33-39.
20. Mond JJ, Lees A, Snapper CM. T cell-independent antigens type 2. Annu Rev Immunol 1995; 13: 655-92.
21. Deisenhammer F, Reindl M, Berger T. Immunoglobulin subclasses in patients with neutralizing and non-neutralizing antibodies against IFN-beta1b. J Interferon Cytokine Res 2001; 21: 167-71.